Heron Therapeutics (HRTX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Heron Therapeutics (HRTX) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.27 of bullish evidence against -0.34 bearish.

Heron Therapeutics last closed at $0.37, +5.71% on the session.

Against the IVW growth benchmark the position is +4.79% over the forecast window.

The read is built from 11 underlying insights — 3 bullish and 8 bearish.

Agreement across those insights is 73%.

16 graded predictions for HRTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Heron Therapeutics in the 2nd percentile on return on equity, where 100 is best.

Heron Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $65.99M.

StockMap tracks Heron Therapeutics as the 272nd largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Heron Therapeutics ranks 166th of 344 in the group, against a group median of -0.21.